A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

作者：Hosseinzadeh Sahar; Bolhassani Azam^*; Rafati Sima; Taheri Tahereh; Zahedifard Farnaz; Daemi Amin; Taslimi Yasaman; Hashemi Mehrdad; Memarnejadian Arash

来源：Drug Delivery, 2013, 20(3-4): 190-198.

DOI：10.3109/10717544.2013.801534

• Cervical cancer
• E7
• glycoprotein 96 (Gp96)
• human papillomavirus (HPV)
• Leishmania tarentolae (L. tar)
• live vaccine

The attenuated or non-pathogenic live vectors have been evolved specifically to deliver DNA into cells as efficient delivery tools in gene therapy. Recently, a non-pathogenic protozoan, Leishmania tarentolae (L.tar) has attracted a great attention. In current study, we used Leishmania expression system (LEXSY) for stable expression of HPV16 E7 linked to different mini-chaperones [N-/C-terminal of gp96] and compared their immunogenicity and protective effects in C57BL/6 mice against TC-1 challenge. TC-1 murine model is primary C57BL/6 mice lung epithelial cells co-transformed with HPV16 E6, HPV16 E7 and ras oncogenes. Our results showed that subcutaneous administration of mice with both the recombinant L.tar-E7-NT (gp96) and L.tar-E7-CT (gp96) led to enhance the levels of IFN-gamma and also IgG2a before and after challenge with TC-1. Furthermore, L.tar-E7-CT (gp96) live vaccine indicated significant protective effects as compared to control groups as well as group vaccinated with L.tar-E7. Indeed, the recombinant live vector is capable of eliciting effective humoral and cellular immune responses in mice, but however, further studies are required to increase their efficacy.

• 出版日期2013-5